×
返回 $name
Session 3 - The Second Impact of ICH and Its Impact on the Operations in Japan
Session Chair(s)
Mitsuo Hayashi, MSC, RPH
Director & Head, Clinical Enablement, MSD K.K., Japan
Toshiko Ishibashi, PHD, RN
Oncology Medical Science Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd., Japan
Speaker(s)
Hideki Suganami, PHD
Global Data Science Center, Head , Kowa Company, Ltd., Japan
New Concepts in the E9 (R1) Guideline
Takahiro Araki, MD, PHD
Senior Clinical Science Director, Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Japan
Will the E17 Guideline Change the Conduct of Multi-Regional Clinical Trials (MRCTs)?